Titre : Cellules THP-1

Cellules THP-1 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Neoplasm Recurrence, Local
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Cellules THP-1 : Questions médicales les plus fréquentes", "headline": "Cellules THP-1 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Cellules THP-1 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-26", "dateModified": "2025-03-21", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Cellules THP-1" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Lignée cellulaire tumorale", "url": "https://questionsmedicales.fr/mesh/D045744", "about": { "@type": "MedicalCondition", "name": "Lignée cellulaire tumorale", "code": { "@type": "MedicalCode", "code": "D045744", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.251.860.180" } } }, "about": { "@type": "MedicalCondition", "name": "Cellules THP-1", "alternateName": "THP-1 Cells", "code": { "@type": "MedicalCode", "code": "D000074084", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Terumasa Ikeda", "url": "https://questionsmedicales.fr/author/Terumasa%20Ikeda", "affiliation": { "@type": "Organization", "name": "2 Institute for Molecular Virology, Minneapolis, MN 55455, USA." } }, { "@type": "Person", "name": "Michael A Carpenter", "url": "https://questionsmedicales.fr/author/Michael%20A%20Carpenter", "affiliation": { "@type": "Organization", "name": "3 Center for Genome Engineering, Minneapolis, MN 55455, USA." } }, { "@type": "Person", "name": "William L Brown", "url": "https://questionsmedicales.fr/author/William%20L%20Brown", "affiliation": { "@type": "Organization", "name": "4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA." } }, { "@type": "Person", "name": "Reuben S Harris", "url": "https://questionsmedicales.fr/author/Reuben%20S%20Harris", "affiliation": { "@type": "Organization", "name": "3 Center for Genome Engineering, Minneapolis, MN 55455, USA." } }, { "@type": "Person", "name": "Valentina Galbiati", "url": "https://questionsmedicales.fr/author/Valentina%20Galbiati", "affiliation": { "@type": "Organization", "name": "Università Degli Studi di Milano, Laboratory of Toxicology, Dipartimento di Scienze Politiche ed Ambientali, Milan, Italy." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Postoperative venous thromboembolism after surgery for locally recurrent rectal cancer.", "datePublished": "2024-08-20", "url": "https://questionsmedicales.fr/article/39164626", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12885-024-12799-1" } }, { "@type": "ScholarlyArticle", "name": "Examination of the effectiveness of local therapy for oligo-recurrence of EGFR-mutated NSCLC.", "datePublished": "2023-01-31", "url": "https://questionsmedicales.fr/article/36720507", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/1759-7714.14805" } }, { "@type": "ScholarlyArticle", "name": "Development of a consensus-based delineation guideline for locally recurrent rectal cancer.", "datePublished": "2022-11-21", "url": "https://questionsmedicales.fr/article/36410547", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.radonc.2022.11.008" } }, { "@type": "ScholarlyArticle", "name": "The clinical relevance of various methods of classifying ipsilateral breast tumour recurrence as either true local recurrence or new primary.", "datePublished": "2022-08-08", "url": "https://questionsmedicales.fr/article/35939185", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10549-022-06680-7" } }, { "@type": "ScholarlyArticle", "name": "Optimal surveillance of intraductal papillary mucinous neoplasms of the pancreas focusing on remnant pancreas recurrence after surgical resection.", "datePublished": "2022-05-29", "url": "https://questionsmedicales.fr/article/35643422", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12885-022-09650-w" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Cellules", "item": "https://questionsmedicales.fr/mesh/D002477" }, { "@type": "ListItem", "position": 3, "name": "Cellules cultivées", "item": "https://questionsmedicales.fr/mesh/D002478" }, { "@type": "ListItem", "position": 4, "name": "Cellules cancéreuses en culture", "item": "https://questionsmedicales.fr/mesh/D014407" }, { "@type": "ListItem", "position": 5, "name": "Lignée cellulaire tumorale", "item": "https://questionsmedicales.fr/mesh/D045744" }, { "@type": "ListItem", "position": 6, "name": "Cellules THP-1", "item": "https://questionsmedicales.fr/mesh/D000074084" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Cellules THP-1 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Cellules THP-1", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Cellules THP-1", "description": "Comment identifier les cellules THP-1 en laboratoire ?\nQuels tests sont utilisés pour caractériser les cellules THP-1 ?\nLes cellules THP-1 peuvent-elles être contaminées ?\nQuelle est la source des cellules THP-1 ?\nLes cellules THP-1 sont-elles sensibles à des médicaments ?", "url": "https://questionsmedicales.fr/mesh/D000074084?mesh_terms=Neoplasm+Recurrence,+Local&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Cellules THP-1", "description": "Quels sont les marqueurs d'activation des cellules THP-1 ?\nLes cellules THP-1 montrent-elles des signes d'inflammation ?\nComment les cellules THP-1 réagissent-elles aux pathogènes ?\nLes cellules THP-1 peuvent-elles se différencier ?\nQuels effets ont les cytokines sur les cellules THP-1 ?", "url": "https://questionsmedicales.fr/mesh/D000074084?mesh_terms=Neoplasm+Recurrence,+Local&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Cellules THP-1", "description": "Comment prévenir la contamination des cellules THP-1 ?\nQuelles conditions de culture sont idéales pour les cellules THP-1 ?\nLes cellules THP-1 nécessitent-elles des soins particuliers ?\nComment assurer la viabilité des cellules THP-1 ?\nLes cellules THP-1 peuvent-elles être cryogénisées ?", "url": "https://questionsmedicales.fr/mesh/D000074084?mesh_terms=Neoplasm+Recurrence,+Local&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Cellules THP-1", "description": "Comment les cellules THP-1 sont-elles utilisées en recherche ?\nPeut-on modifier génétiquement les cellules THP-1 ?\nQuels traitements sont testés sur les cellules THP-1 ?\nLes cellules THP-1 peuvent-elles être utilisées pour des tests de toxicité ?\nComment les cellules THP-1 aident-elles à comprendre les maladies ?", "url": "https://questionsmedicales.fr/mesh/D000074084?mesh_terms=Neoplasm+Recurrence,+Local&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Cellules THP-1", "description": "Quelles complications peuvent survenir lors de l'utilisation des cellules THP-1 ?\nLes cellules THP-1 peuvent-elles induire des réponses immunitaires indésirables ?\nQuels risques sont associés à la manipulation des cellules THP-1 ?\nLes cellules THP-1 peuvent-elles être affectées par des agents externes ?\nComment minimiser les complications lors des expériences avec THP-1 ?", "url": "https://questionsmedicales.fr/mesh/D000074084?mesh_terms=Neoplasm+Recurrence,+Local&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Cellules THP-1", "description": "Quels facteurs influencent la croissance des cellules THP-1 ?\nLes cellules THP-1 sont-elles sensibles à des agents environnementaux ?\nQuels traitements peuvent affecter les cellules THP-1 ?\nLes cellules THP-1 sont-elles affectées par le stress oxydatif ?\nQuels facteurs génétiques influencent les cellules THP-1 ?", "url": "https://questionsmedicales.fr/mesh/D000074084?mesh_terms=Neoplasm+Recurrence,+Local&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier les cellules THP-1 en laboratoire ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Les cellules THP-1 sont identifiées par leur morphologie et leur expression de marqueurs spécifiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour caractériser les cellules THP-1 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests comme la cytométrie en flux et l'immunofluorescence sont utilisés." } }, { "@type": "Question", "name": "Les cellules THP-1 peuvent-elles être contaminées ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, comme toutes les lignées cellulaires, elles peuvent être contaminées par des bactéries ou des mycoplasmes." } }, { "@type": "Question", "name": "Quelle est la source des cellules THP-1 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les cellules THP-1 proviennent de la moelle osseuse d'un patient atteint de leucémie." } }, { "@type": "Question", "name": "Les cellules THP-1 sont-elles sensibles à des médicaments ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont souvent utilisées pour tester la sensibilité à divers agents pharmacologiques." } }, { "@type": "Question", "name": "Quels sont les marqueurs d'activation des cellules THP-1 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les marqueurs incluent CD14, CD11b et CD68, indiquant leur activation." } }, { "@type": "Question", "name": "Les cellules THP-1 montrent-elles des signes d'inflammation ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles produisent des cytokines pro-inflammatoires lorsqu'elles sont activées." } }, { "@type": "Question", "name": "Comment les cellules THP-1 réagissent-elles aux pathogènes ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elles phagocytent les pathogènes et sécrètent des médiateurs inflammatoires." } }, { "@type": "Question", "name": "Les cellules THP-1 peuvent-elles se différencier ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent se différencier en macrophages sous l'influence de certains facteurs." } }, { "@type": "Question", "name": "Quels effets ont les cytokines sur les cellules THP-1 ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les cytokines modulent leur activation et leur capacité à produire d'autres médiateurs." } }, { "@type": "Question", "name": "Comment prévenir la contamination des cellules THP-1 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des techniques aseptiques et vérifier régulièrement la pureté cellulaire." } }, { "@type": "Question", "name": "Quelles conditions de culture sont idéales pour les cellules THP-1 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Elles nécessitent un milieu riche en nutriments et une température contrôlée." } }, { "@type": "Question", "name": "Les cellules THP-1 nécessitent-elles des soins particuliers ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles doivent être manipulées avec précaution pour éviter le stress cellulaire." } }, { "@type": "Question", "name": "Comment assurer la viabilité des cellules THP-1 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir des conditions optimales de culture et éviter les cycles de congélation-décongélation." } }, { "@type": "Question", "name": "Les cellules THP-1 peuvent-elles être cryogénisées ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent être cryogénisées pour une conservation à long terme." } }, { "@type": "Question", "name": "Comment les cellules THP-1 sont-elles utilisées en recherche ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont utilisées pour étudier les mécanismes immunitaires et tester des médicaments." } }, { "@type": "Question", "name": "Peut-on modifier génétiquement les cellules THP-1 ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des techniques comme CRISPR peuvent être utilisées pour modifier leur génome." } }, { "@type": "Question", "name": "Quels traitements sont testés sur les cellules THP-1 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements anti-inflammatoires et anticancéreux sont souvent testés." } }, { "@type": "Question", "name": "Les cellules THP-1 peuvent-elles être utilisées pour des tests de toxicité ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont souvent utilisées pour évaluer la toxicité des composés chimiques." } }, { "@type": "Question", "name": "Comment les cellules THP-1 aident-elles à comprendre les maladies ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Elles modélisent des maladies inflammatoires et infectieuses pour étudier les mécanismes." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir lors de l'utilisation des cellules THP-1 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des résultats biaisés peuvent survenir si les cellules sont contaminées ou mal caractérisées." } }, { "@type": "Question", "name": "Les cellules THP-1 peuvent-elles induire des réponses immunitaires indésirables ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent parfois produire des réponses immunitaires non spécifiques." } }, { "@type": "Question", "name": "Quels risques sont associés à la manipulation des cellules THP-1 ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Le risque principal est la contamination croisée avec d'autres lignées cellulaires." } }, { "@type": "Question", "name": "Les cellules THP-1 peuvent-elles être affectées par des agents externes ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des agents comme les toxines ou les médicaments peuvent altérer leur fonction." } }, { "@type": "Question", "name": "Comment minimiser les complications lors des expériences avec THP-1 ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Suivre des protocoles stricts et effectuer des contrôles réguliers de qualité." } }, { "@type": "Question", "name": "Quels facteurs influencent la croissance des cellules THP-1 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme la température, le pH et la composition du milieu influencent leur croissance." } }, { "@type": "Question", "name": "Les cellules THP-1 sont-elles sensibles à des agents environnementaux ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent être affectées par des agents chimiques ou physiques dans leur environnement." } }, { "@type": "Question", "name": "Quels traitements peuvent affecter les cellules THP-1 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements comme les cytokines ou les médicaments peuvent moduler leur activité." } }, { "@type": "Question", "name": "Les cellules THP-1 sont-elles affectées par le stress oxydatif ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress oxydatif peut altérer leur fonction et leur viabilité." } }, { "@type": "Question", "name": "Quels facteurs génétiques influencent les cellules THP-1 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Des variations génétiques peuvent affecter leur réponse aux stimuli immunitaires." } } ] } ] }

Sources (10000 au total)

Postoperative venous thromboembolism after surgery for locally recurrent rectal cancer.

Local recurrence is common after curative resections of rectal cancer. Surgical resection is considered a primary curative treatment option for patients with locally recurrent rectal cancer (LRRC). LR... From April 2010 to March 2022, a total of 166 patients underwent surgery for LRRC in the pelvic region at our institutions. Clinicopathological background and VTE incidence were compared retrospective... Among the 166 patients included in the study, 55 patients (33.1%) needed sacral resection. Pharmacological prophylaxis for prevention of VTE was performed in 121 patients (73.3%), and the incidence of... This study demonstrates that surgery for LRRC combined with sacral resection could be a significant risk factor for VTE....

Examination of the effectiveness of local therapy for oligo-recurrence of EGFR-mutated NSCLC.

The effectiveness of local therapy has been reported in patients with oligo-recurrence of non-small cell lung cancer (NSCLC), a metachronous recurrence with a limited number of recurrences, which can ... From 2004 to 2014, 811 patients underwent complete resection for NSCLC at Kitasato University Hospital and, of these, 244 patients developed recurrence. Oligo-recurrence was defined as the presence of... We retrospectively examined and compared the effects of EGFR-TKIs with those of radical local therapy in patients with oligo-recurrent EGFR-mutated NSCLC. The five-year post-recurrence survival (PRS) ... Radical local therapy did not affect PRS in patients with oligo-recurrent EGFR-mutated NSCLC. Even in cases of oligo-recurrence, the administration of local therapy in patients with EGFR-mutated NSCLC...

Development of a consensus-based delineation guideline for locally recurrent rectal cancer.

Neoadjuvant chemoradiotherapy (nCRT) is used in locally recurrent rectal cancer (LRRC) to increase chances of a radical surgical resection. Delineation in LRRC is hampered by complex disease presentat... Eight radiation oncologists, from Dutch and Swedish expert centres, participated in two meetings, delineating GTV and CTV in six cases. Regions at-risk for re-recurrence or irradical resection were id... Inter-observer variation in delineation of LRRC appeared large. Multidisciplinary evaluation per case is beneficial in determining target volumes. The following consensus regarding target volumes was ... This study provides a first consensus-based delineation guideline for LRRC. Analyses of re-recurrences is needed to understand disease behaviour and to optimize delineation guidelines accordingly....

The clinical relevance of various methods of classifying ipsilateral breast tumour recurrence as either true local recurrence or new primary.

Describes the relevance of -various classification methods for ipsilateral breast tumour recurrence (IBTR) as either true recurrence (TR) or new primary (NP) on both disease-specific survival (DSS) an... Two hundred and thirty-four of 4359 women undergoing breast-conserving therapy experienced IBTR. We compared the impact of four known classification methods and two newly created classification method... For three of the methods, a better DSS was observed for NP compared to TR with the hazard ratio (HR) ranging from 0.5 to 0.6. The new Twente method classification, comprising all classification criter... IBTR classified as TR or NP has a prognostic value for both DSS and DMFS, but depends on the classification method used. Developing and validating a generally accepted form of classification are imper...

Optimal surveillance of intraductal papillary mucinous neoplasms of the pancreas focusing on remnant pancreas recurrence after surgical resection.

The international consensus guidelines for intraductal papillary mucinous neoplasm of the pancreas (IPMN) presented clinical features as indications for surgery. Whereas surveillance for recurrence, i... This study aimed to assess the clinical features of recurrence at the remnant pancreas (Rem-Panc) and extra-pancreas (Ex-Panc) after surgery for IPMN. Ninety-one patients of IPMN that underwent detail... The IPMNs were finally diagnosed as low-grade dysplasia (LDA, n = 42), high-grade dysplasia (HAD, n = 19), and invasive carcinoma (IPMC, n = 30). Recurrence was observed in 26 patients (29%), of which... The risk factors for Rem-Panc and Ex-Panc recurrence differ. Therefore, optimal surveillance on these features is desirable to ensure that repeat pancreatectomy for Rem-Panc recurrence can be an appro...

Brain magnetic resonance spectroscopy to differentiate recurrent neoplasm from radiation necrosis: A systematic review and meta-analysis.

Postradiation treatment necrosis is one of the most serious late sequelae and appears within 6 months. The magnetic resonance spectroscopy imaging (MRSI) has been used for the detection of brain tumor... The research was performed in accordance with the preferred reporting items for systematic review and meta-analysis guidelines. International electronic databases including 15 English sources were inv... Nine studies were enrolled in the meta-analysis with a total of 354 patients (203 male and 151 female) whose average age ranged from 4 to 74 years. Anbarloui et al., Elias et al., Nemattalla et al., S... MR spectroscopy is effective in distinguishing recurrent brain tumors from necrosis. Our meta-analysis revealed that Cho/NAA, Cho/Cr, and NAA/Cr ratios were significantly better predictor of detected ...

A systematic review of the pathological determinants of outcome following resection by pelvic exenteration of locally advanced and locally recurrent rectal cancer.

Despite multimodal therapy 5-15% of patients who undergo resection for advanced rectal cancer (LARC) will develop local recurrence. Management of locally recurrent rectal cancer (LRRC) presents a sign... A systematic review was carried out searching MEDLINE, EMBASE and COCHRANE Trials database for all studies assessing pathological factors influencing survival following pelvic exenteration for LARC or... Nine cohort studies met inclusion criteria, reporting outcomes for 2864 patients. Meta-analysis was not possible due to significant heterogeneity of reported outcomes. Resection margin status and noda... Pathological resection margin status is widely demonstrated to influence disease free and overall survival following pelvic exenteration for rectal cancer. With increasing R0 rates, other adverse tumo...

Image-guided navigation for locally advanced primary and locally recurrent rectal cancer: evaluation of its early cost-effectiveness.

A first pilot study showed that an image-guided navigation system could improve resection margin rates in locally advanced (LARC) and locally recurrent rectal cancer (LRRC) patients. Incremental surgi... A Markov decision model was constructed to estimate the expected costs and outcomes for navigated and standard surgery. The input parameters were based on pilot data from a prospective (navigation coh... Based on this early evaluation, navigated surgery showed incremental costs of €3141 and €2896 in LARC and LRRC. In LARC, navigated surgery resulted in 2.05 Quality-Adjusted Life Years (QALYs) vs 2.02 ... Adding navigation system use is expected to be cost-effective in LRRC and has the potential to become cost-effective in LARC. To increase the probability of being cost-effective, it is crucial to opti...

The role of surgery in recurrent local cerebral metastases: a multi-institutional retrospective analysis.

Local recurrent brain metastases are defined as lesions that recur in the brain at the same site after a previous local therapy. In patients already submitted to surgery, a second operation may be pot... 37 patients submitted to surgery for a local, histologically confirmed, recurrent brain metastases between 2000 and 2022 were retrospectively analyzed with respect to the following parameters: age, hi... A significant improvement of post-operative KPS status was obtained after second surgery. At multivariate analysis better results in terms of OS were achieved in patients with a pre-operative KPS ≥ 70... Surgical resection of local recurrent brain metastases may improve patients ́ neurologic conditions allowing more time for systemic therapies to act with a low incidence of surgery-related morbidity a...

Salvage radiotherapy for locally recurrent cervical and endometrial carcinoma: clinical outcomes and toxicities.

The management of locally recurrent gynecological carcinoma remains a challenge due to the limited availability of data. This study aims to share our institutional experience in using definitive radio... The study retrospectively reviewed 20 patients in our hospital completing salvage 3D image-based HDR brachytherapy, with or without EBRT, for locally recurrent cervical and endometrial carcinoma after... During a median observation period of 21 months, the study reported a tumor objective response rate of 95%. The 3-year DFS and OS rates were 89.4% and 90.9%, respectively. The EBRT combined with brach... 3D image-guided brachytherapy combined with EBRT shows effective tumor control and acceptable toxicity profile for women with locally recurrent gynecologic cancer. The success in managing vaginal recu...